Henry Schein Maintains 'Hold' Rating Despite Earnings Beat and Strong 2026 Outlook

Henry Schein (HSIC) has received a consensus "Hold" recommendation from thirteen brokerage firms, indicating a neutral stance among analysts despite recent financial growth. The average one-year price target for the stock has been set at $85.58 following the latest market updates. This rating persists even as the company outperformed quarterly earnings and revenue expectations while issuing robust EPS guidance for fiscal year 2026. Balancing these positive results, insider sales totaled approximately $8.57 million over the past three months, which may have tempered investor enthusiasm. Institutional investors continue to hold a dominant position in the company, owning 96.62% of the outstanding shares. The combination of strong operational performance and significant insider activity suggests a stable but cautious outlook for the healthcare distributor in the near term.